Sales ended at MNOK 57.3 for the quarter (MNOK 47.9), a 19.6 % growth. Sales for the 1st half increased by 19.1 % and ended at MOK 115.2 (MNOK 96.7). Operating profit (EBIT) for the quarter ended at MNOK 11.7 (MNOK 11.7) after an accrual of MNOK 3.2 related to termination of the Medtronic agreement. Operating profit for the 1st half ended at MNOK 21.6 (MNOK 18.9). Profit per share increased with 45 % for the quarter and ended at NOK 0.58 (NOK 0.40).

There was a positive development in USA with 40 % increase in sales in the 2nd quarter and 45 % for the first half. Medistim strengthens it US operation by increasing its sales force. Medistim is sponsoring REQUEST, a pioneer multicenter register study performed by leading hospitals in Europe and North.

Q2 2015 presentation